These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36810103)

  • 21. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
    Erdos J; Wild C
    Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study.
    Kiefer P; Kirschner J; Pechmann A; Langer T
    Orphanet J Rare Dis; 2020 Jul; 15(1):194. PubMed ID: 32727502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 27. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
    Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
    Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spontaneous Breathing Pattern as Respiratory Functional Outcome in Children with Spinal Muscular Atrophy (SMA).
    LoMauro A; Aliverti A; Mastella C; Arnoldi MT; Banfi P; Baranello G
    PLoS One; 2016; 11(11):e0165818. PubMed ID: 27820869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The International Classification of Functioning, Disability and Health-Children and Youth as a framework for the management of spinal muscular atrophy in the era of gene therapy: a proof-of-concept study.
    Trabacca A; Lucarelli E; Pacifico R; Vespino T; Di Liddo A; Losito L
    Eur J Phys Rehabil Med; 2020 Apr; 56(2):243-251. PubMed ID: 31939268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
    Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
    Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mixed method study on the impact of living with spinal muscular atrophy in Malaysia from patients' and caregivers' perspectives.
    Ch'ng GS; Koh K; Ahmad-Annuar A; Taib F; Koh CL; Lim ESC
    Orphanet J Rare Dis; 2022 May; 17(1):200. PubMed ID: 35578241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen.
    Meyer T; Maier A; Uzelac Z; Hagenacker T; Günther R; Schreiber-Katz O; Weiler M; Steinbach R; Weyen U; Koch JC; Kettemann D; Norden J; Dorst J; Wurster C; Ludolph AC; Stolte B; Freigang M; Osmanovic A; Petri S; Grosskreutz J; Rödiger A; Griep R; Gaudlitz M; Walter B; Münch C; Spittel S
    Eur J Neurol; 2021 Aug; 28(8):2582-2595. PubMed ID: 33960080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study.
    Yao M; Ma Y; Qian R; Xia Y; Yuan C; Bai G; Mao S
    Orphanet J Rare Dis; 2021 Jan; 16(1):7. PubMed ID: 33407670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
    Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
    Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
    Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
    BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risdiplam for the Use of Spinal Muscular Atrophy.
    Kakazu J; Walker NL; Babin KC; Trettin KA; Lee C; Sutker PB; Kaye AM; Kaye AD
    Orthop Rev (Pavia); 2021; 13(2):25579. PubMed ID: 34745484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1.
    Zappa G; LoMauro A; Baranello G; Cavallo E; Corti P; Mastella C; Costantino MA
    J Neurodev Disord; 2021 Feb; 13(1):9. PubMed ID: 33530934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.